Cross-Sector entity
Of the tracked stories, 2 of 2 also mention BioLife Solutions, the most common co-covered peer. Coverage clusters in medical-devices, which accounts for 1 of those 2, with the remainder spread across 1 other category. Pacira BioSciences appears in 2 tracked Cross-Sector stories from February 27, 2026.
2 verified stories tracked
Last mentioned: Feb 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 2 of 2 also mention BioLife Solutions, the most common co-covered peer. Coverage clusters in medical-devices, which accounts for 1 of those 2, with the remainder spread across 1 other category. Pacira BioSciences appears in 2 tracked Cross-Sector stories from February 27, 2026. The tracked stories average 19 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Pacira BioSciences. Shared-story counts are live from our verified record — not editorial picks.
The final quarter of 2025 revealed a sector-wide shift toward operational discipline and high-margin product expansion among leading biotech and pharma entities. Key players like Indivior and Pacira reported significant volume growth in flagship therapies while successfully navigating patent challenges and portfolio optimizations.
The fourth quarter of 2025 revealed a decisive shift in the healthcare technology sector toward AI-integrated diagnostics and high-margin specialized therapies. Leading the charge, Butterfly Network reported record revenue growth driven by its AI-embedded strategy, while Solventum navigated its post-spin-off stabilization phase with resilient organic growth.
